PTC Therapeutics Stock Price, News & Analysis (NASDAQ:PTCT)

$21.92 0.99 (4.73 %)
(As of 01/19/2018 04:00 PM ET)
Previous Close$21.92
Today's Range$20.80 - $22.35
52-Week Range$8.12 - $23.71
Volume1.28 million shs
Average Volume883,095 shs
Market Capitalization$868.38 million
P/E Ratio-7.58
Dividend YieldN/A
Beta1.23

About PTC Therapeutics (NASDAQ:PTCT)

PTC Therapeutics logoPTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF). PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. RG7916 is an investigational oral therapeutic, which is in two clinical studies: SUNFISH, a trial in childhood onset (Type II/III) spinal muscular atrophy (SMA) patients, and FIREFISH, a trial in infant onset (Type I) SMA patients.

Receive PTCT News and Ratings via Email

Sign-up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PTCT
CUSIPN/A
Phone908-222-7000

Debt

Debt-to-Equity Ratio0.98%
Current Ratio3.08%
Quick Ratio2.97%

Price-To-Earnings

Trailing P/E Ratio-7.58474884169951
Forward P/E Ratio-10.91
P/E GrowthN/A

Sales & Book Value

Annual Sales$82.71 million
Price / Sales11.00
Cash FlowN/A
Price / CashN/A
Book Value$3.48 per share
Price / Book6.30

Profitability

Trailing EPS($2.89)
Net Income$-142,110,000.00
Net Margins-75.64%
Return on Equity-75.19%
Return on Assets-31.76%

Miscellaneous

Employees304
Outstanding Shares41,490,000

PTC Therapeutics (NASDAQ:PTCT) Frequently Asked Questions

What is PTC Therapeutics' stock symbol?

PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."

How were PTC Therapeutics' earnings last quarter?

PTC Therapeutics, Inc. (NASDAQ:PTCT) issued its quarterly earnings data on Thursday, November, 2nd. The biopharmaceutical company reported ($0.67) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.66) by $0.01. PTC Therapeutics had a negative net margin of 75.64% and a negative return on equity of 75.19%. View PTC Therapeutics' Earnings History.

When will PTC Therapeutics make its next earnings announcement?

PTC Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 14th 2018. View Earnings Estimates for PTC Therapeutics.

Where is PTC Therapeutics' stock going? Where will PTC Therapeutics' stock price be in 2018?

8 brokerages have issued 12-month price objectives for PTC Therapeutics' stock. Their forecasts range from $15.00 to $28.00. On average, they expect PTC Therapeutics' share price to reach $19.17 in the next twelve months. View Analyst Ratings for PTC Therapeutics.

What are Wall Street analysts saying about PTC Therapeutics stock?

Here are some recent quotes from research analysts about PTC Therapeutics stock:

  • 1. According to Zacks Investment Research, "PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States. " (1/13/2018)
  • 2. Cowen Inc analysts commented, "Yesterday Clearside announced the completion of enrollment in the TYBEE study in." (10/25/2017)
  • 3. Royal Bank of Canada analysts commented, "PTCT has announced it has filed its NDA for ataluren with FDA under protest and that the filing has been acknowledged: Recall that the FDA issued a Refuse-to-File letter on 2/23/16. The NDA was initially filed on 1/8/16 and was based on the results of the confirmatory Phase III ACTDMD trial, released 10/15/15, which failed to meet its primary endpoint. We continue to see very little chance that ataluren gets approved in the US, given compelling evidence from multiple randomized clinical trials where this compound failed to meet its primary endpoint. We believe that despite what looks like an improving/lower-threshold FDA environment, the only way this compound can get approval is if it succeeds in a new Phase III trial. Absent that, we believe that the key opportunity to evaluate in PTCT shares are Translarna ex-US sales, which we view as fully valued at current levels. We reiterate our Sector Perform rating on PTCT." (3/6/2017)

Who are some of PTC Therapeutics' key competitors?

Who are PTC Therapeutics' key executives?

PTC Therapeutics' management team includes the folowing people:

  • Michael Schmertzler, Independent Chairman of the Board (Age 65)
  • Stuart W. Peltz Ph.D., Chief Executive Officer, Director (Age 57)
  • Christine Marie Utter, Principal Financial Officer, Principal Accounting Officer, Treasurer (Age 39)
  • Marcio Souza, Chief Operating Officer (Age 38)
  • Mark E. Boulding, Executive Vice President, Chief Legal Officer and Corporate Secretary (Age 55)
  • Neil Almstead Ph.D., Executive Vice President, Research, Pharmaceutical Operations & Technology (Age 50)
  • Tuyen Ong, Chief Medical Officer (Age 42)
  • Allan S. Jacobson Ph.D., Independent Director (Age 71)
  • David P. Southwell, Independent Director (Age 56)
  • Glenn D. Steele Jr., M.D., Ph.D., Independent Director (Age 72)

Who owns PTC Therapeutics stock?

PTC Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Schwab Charles Investment Management Inc. (0.45%), Frontier Capital Management Co. LLC (0.25%) and Creative Planning (0.03%). Company insiders that own PTC Therapeutics stock include Christine Marie Utter, Dawn Svoronos, Mark Rothera, Neil Gregory Almstead and Stuart Walter Peltz. View Institutional Ownership Trends for PTC Therapeutics.

Who sold PTC Therapeutics stock? Who is selling PTC Therapeutics stock?

PTC Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC. Company insiders that have sold PTC Therapeutics company stock in the last year include Christine Marie Utter, Neil Gregory Almstead and Stuart Walter Peltz. View Insider Buying and Selling for PTC Therapeutics.

Who bought PTC Therapeutics stock? Who is buying PTC Therapeutics stock?

PTC Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Creative Planning and Schwab Charles Investment Management Inc.. Company insiders that have bought PTC Therapeutics stock in the last two years include Dawn Svoronos and Mark Rothera. View Insider Buying and Selling for PTC Therapeutics.

How do I buy PTC Therapeutics stock?

Shares of PTC Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PTC Therapeutics' stock price today?

One share of PTC Therapeutics stock can currently be purchased for approximately $21.92.

How big of a company is PTC Therapeutics?

PTC Therapeutics has a market capitalization of $868.38 million and generates $82.71 million in revenue each year. The biopharmaceutical company earns $-142,110,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis. PTC Therapeutics employs 304 workers across the globe.

How can I contact PTC Therapeutics?

PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The biopharmaceutical company can be reached via phone at 908-222-7000 or via email at [email protected]


MarketBeat Community Rating for PTC Therapeutics (PTCT)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  308 (Vote Outperform)
Underperform Votes:  289 (Vote Underperform)
Total Votes:  597
MarketBeat's community ratings are surveys of what our community members think about PTC Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

PTC Therapeutics (NASDAQ:PTCT) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.132.112.112.22
Ratings Breakdown: 1 Sell Rating(s)
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $19.17$18.14$16.38$15.25
Price Target Upside: 21.00% upside14.54% upside16.58% downside21.51% downside

PTC Therapeutics (NASDAQ:PTCT) Consensus Price Target History

Price Target History for PTC Therapeutics (NASDAQ:PTCT)

PTC Therapeutics (NASDAQ:PTCT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/24/2017JPMorgan Chase & Co.Boost Price TargetUnderweight -> Neutral$15.00N/AView Rating Details
10/26/2017Bank of AmericaDowngradeNeutral -> UnderperformN/AView Rating Details
10/25/2017CowenReiterated RatingHoldN/AView Rating Details
10/25/2017Royal Bank of CanadaSet Price TargetHold$15.00N/AView Rating Details
9/29/2017BarclaysLower Price TargetEqual Weight -> Equal Weight$22.00 -> $15.00HighView Rating Details
9/27/2017CitigroupReiterated RatingBuy$28.00LowView Rating Details
9/26/2017Credit Suisse GroupReiterated RatingOutperform$25.00HighView Rating Details
8/23/2017William BlairInitiated CoverageMkt Perform -> Market Perform$17.00LowView Rating Details
1/10/2017Jefferies GroupReiterated RatingHold$12.00N/AView Rating Details
11/11/2016WedbushReiterated RatingNeutral$12.00 -> $7.00N/AView Rating Details
4/17/2016OppenheimerReiterated RatingBuy$39.00N/AView Rating Details
(Data available from 1/20/2016 forward)

Earnings

PTC Therapeutics (NASDAQ:PTCT) Earnings History and Estimates Chart

Earnings by Quarter for PTC Therapeutics (NASDAQ:PTCT)

PTC Therapeutics (NASDAQ PTCT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/14/2018($0.35)N/AView Earnings Details
11/2/2017Q3 2017($0.66)($0.67)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.89)($0.44)$28.78 million$47.96 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.88)($0.85)$27.93 million$26.50 millionViewListenView Earnings Details
3/16/201712/31/2016($1.07)($0.78)$24.69 million$25.20 millionViewN/AView Earnings Details
11/2/2016Q316($1.22)($1.03)$19.76 million$23.00 millionViewN/AView Earnings Details
8/4/2016Q216($1.27)($1.14)$15.24 million$15.40 millionViewN/AView Earnings Details
5/5/2016Q116($1.26)($1.22)$13.74 million$18.90 millionViewN/AView Earnings Details
2/29/2016Q415($1.25)($1.50)$13.04 million$12.70 millionViewListenView Earnings Details
11/9/2015Q315($1.15)($1.27)$9.88 million$9.78 millionViewListenView Earnings Details
7/30/2015Q215($1.20)($1.14)$7.73 million$6.77 millionViewListenView Earnings Details
5/4/2015Q115($1.20)($1.15)$2.97 million$7.50 millionViewN/AView Earnings Details
2/27/2015Q414($0.83)($0.84)$7.99 million$12.70 millionViewListenView Earnings Details
11/6/2014Q314($0.90)($0.93)$1.76 million$1.69 millionViewN/AView Earnings Details
8/7/2014Q214($0.75)($0.86)$1.71 million$1.70 millionViewN/AView Earnings Details
5/6/2014($0.46)($0.58)$10.93 million$9.22 millionViewN/AView Earnings Details
3/6/2014Q413($0.57)($0.75)$6.15 million$4.40 millionViewN/AView Earnings Details
11/14/2013Q3($0.29)($0.19)$7.20 million$16.29 millionViewListenView Earnings Details
8/13/2013Q2 2013($0.71)($5.51)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

PTC Therapeutics (NASDAQ:PTCT) Earnings Estimates

2018 EPS Consensus Estimate: ($1.05)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.30)($0.30)($0.30)
Q2 20181($0.27)($0.27)($0.27)
Q3 20181($0.25)($0.25)($0.25)
Q4 20181($0.23)($0.23)($0.23)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for PTC Therapeutics (NASDAQ:PTCT)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

PTC Therapeutics (NASDAQ PTCT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.10%
Institutional Ownership Percentage: 86.12%
Insider Trades by Quarter for PTC Therapeutics (NASDAQ:PTCT)
Institutional Ownership by Quarter for PTC Therapeutics (NASDAQ:PTCT)

PTC Therapeutics (NASDAQ PTCT) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/5/2018Stuart Walter PeltzCEOSell2,230$18.03$40,206.9026,646View SEC Filing  
1/4/2018Christine Marie UtterInsiderSell412$17.67$7,280.04View SEC Filing  
1/4/2018Neil Gregory AlmsteadEVPSell77$17.67$1,360.59View SEC Filing  
5/23/2017Dawn SvoronosDirectorBuy25,000$13.49$337,250.0025,000View SEC Filing  
1/5/2017Neil Gregory AlmsteadEVPSell78$11.82$921.96View SEC Filing  
3/3/2016Mark RotheraInsiderBuy2,000$6.23$12,460.005,125View SEC Filing  
7/6/2015David P SouthwellDirectorSell23,604$47.52$1,121,662.08View SEC Filing  
6/18/2015Allan Steven JacobsonDirectorSell5,000$50.13$250,650.00View SEC Filing  
6/9/2015Stuart Walter PeltzCEOSell100,000$54.49$5,449,000.00View SEC Filing  
6/8/2015Mark Elliott BouldingVPSell56,849$55.04$3,128,968.96View SEC Filing  
6/8/2015Richard AldrichDirectorSell7,000$55.66$389,620.00View SEC Filing  
6/8/2015Stuart Walter PeltzCEOSell73,700$54.91$4,046,867.00View SEC Filing  
5/22/2015Shane William Charles KovacsCFOSell82,491$55.41$4,570,826.31View SEC Filing  
4/15/2015Neil Gregory AlmsteadEVPSell9,511$68.65$652,930.15View SEC Filing  
3/23/2015David P SouthwellDirectorSell2,317$69.04$159,965.68View SEC Filing  
3/23/2015Stuart Walter PeltzCEOSell47,200$69.14$3,263,408.00View SEC Filing  
3/20/2015Mark Elliott BouldingVPSell21,142$68.12$1,440,193.04View SEC Filing  
3/18/2015Allan Steven JacobsonDirectorSell16,616$76.00$1,262,816.00View SEC Filing  
3/17/2015Mark RotheraInsiderSell10,700$76.64$820,048.00View SEC Filing  
3/16/2015Michael L KrandaDirectorSell2,500$72.81$182,025.00View SEC Filing  
3/13/2015Robert J SpiegelInsiderSell1,030$75.10$77,353.00View SEC Filing  
3/10/2015Neil Gregory AlmsteadEVPSell79$70.71$5,586.09View SEC Filing  
3/9/2015Stuart Walter PeltzCEOSell47,201$70.74$3,338,998.74View SEC Filing  
2/25/2015Mark RotheraInsiderSell35,000$68.01$2,380,350.00View SEC Filing  
2/24/2015Mark RotheraInsiderSell1,000$67.70$67,700.00View SEC Filing  
2/23/2015Mark RotheraInsiderSell23,000$65.40$1,504,200.00View SEC Filing  
1/21/2015Neil Gregory AlmsteadEVPSell26,096$60.26$1,572,544.96View SEC Filing  
1/20/2015Mark RotheraInsiderSell3,000$60.02$180,060.00View SEC Filing  
1/16/2015Mark RotheraInsiderSell2,300$58.67$134,941.00View SEC Filing  
1/15/2015Claudia De Oliveira Ri HirawatPresidentSell2,149$57.19$122,901.31View SEC Filing  
1/14/2015Mark RotheraInsiderSell9,700$58.04$562,988.00View SEC Filing  
12/15/2014Claudia De Oliveira Ri HirawatPresidentSell2,173$55.24$120,036.52View SEC Filing  
11/17/2014Claudia De Oliveira Ri HirawatPresidentSell2,173$39.78$86,441.94View SEC Filing  
10/15/2014Claudia De Oliveira Ri HirawatPresidentSell45,661$36.15$1,650,645.15View SEC Filing  
10/10/2014Claudia De Oliveira Ri HirawatPresidentSell43,489$36.18$1,573,432.02View SEC Filing  
10/1/2014Stuart Walter PeltzCEOSell41,501$42.65$1,770,017.65View SEC Filing  
9/26/2014Mark RotheraInsiderSell16,000$44.63$714,080.00View SEC Filing  
9/18/2014Allan Steven JacobsonDirectorSell2,000$40.16$80,320.00View SEC Filing  
9/15/2014Mark RotheraInsiderSell8,000$36.24$289,920.00View SEC Filing  
5/22/2014Shane William Charles KovacsCFOSell1,650$14.74$24,321.0012,350View SEC Filing  
3/24/2014Stuart Walter PeltzCEOSell25,487$29.86$761,041.82135,902View SEC Filing  
3/21/2014Claudia De Oliveira Ri HirawatPresidentSell15,320$29.61$453,625.2034,737View SEC Filing  
3/21/2014David SouthwellDirectorSell2,317$30.93$71,664.8110,921View SEC Filing  
3/20/2014Mark Elliott BouldingVPSell10,049$30.96$311,117.0432,235View SEC Filing  
3/19/2014Neil Gregory AlmsteadVPSell10,859$31.91$346,510.6929,881View SEC Filing  
3/18/2014Allan Steven JacobsonDirectorSell7,616$31.18$237,466.8830,464View SEC Filing  
3/14/2014Michael KrandaDirectorSell1,186$31.02$36,789.724,742View SEC Filing  
3/13/2014Robert SpiegelInsiderSell1,186$31.75$37,655.504,269View SEC Filing  
3/7/2014Stuart Walter PeltzCEOSell27,414$29.91$819,952.74161,389View SEC Filing  
12/17/2013Hbm Healthcare Investments (Camajor shareholderSell66,667$19.08$1,272,006.362,441,504View SEC Filing  
6/25/2013Adam KoppelDirectorBuy1,250,000$15.00$18,750,000.00View SEC Filing  
6/25/2013Hbm Healthcare Investments (CaMajor ShareholderBuy666,676$15.00$10,000,140.00View SEC Filing  
6/25/2013Mark RotheraInsiderBuy25,000$15.00$375,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

PTC Therapeutics (NASDAQ PTCT) News Headlines

Source:
DateHeadline
Drugmaker Raises US Price of Muscular-Dystrophy Treatment - Wall Street JournalDrugmaker Raises US Price of Muscular-Dystrophy Treatment - Wall Street Journal
www.wsj.com - January 19 at 4:58 PM
Drugmaker Raises U.S. Price of Muscular-Dystrophy TreatmentDrugmaker Raises U.S. Price of Muscular-Dystrophy Treatment
finance.yahoo.com - January 18 at 4:05 PM
Zacks Investment Research Downgrades PTC Therapeutics (PTCT) to HoldZacks Investment Research Downgrades PTC Therapeutics (PTCT) to Hold
www.americanbankingnews.com - January 13 at 6:26 AM
PTC Therapeutics Target of Unusually High Options Trading (PTCT)PTC Therapeutics Target of Unusually High Options Trading (PTCT)
www.americanbankingnews.com - January 13 at 3:48 AM
FY2017 EPS Estimates for PTC Therapeutics, Inc. Lifted by Analyst (PTCT)FY2017 EPS Estimates for PTC Therapeutics, Inc. Lifted by Analyst (PTCT)
www.americanbankingnews.com - January 10 at 6:30 AM
PTC Therapeutics, Inc. (PTCT) CEO Stuart Walter Peltz Sells 2,230 SharesPTC Therapeutics, Inc. (PTCT) CEO Stuart Walter Peltz Sells 2,230 Shares
www.americanbankingnews.com - January 9 at 7:56 PM
PTC Therapeutics (PTCT) Guides 2018 Revenues Above Consensus; Announces Corporate Update and Strategic Priorities for 2018PTC Therapeutics (PTCT) Guides 2018 Revenues Above Consensus; Announces Corporate Update and Strategic Priorities for 2018
www.streetinsider.com - January 9 at 10:15 AM
PTC Therapeutics (PTCT) Jumps: Stock Rises 12.9%PTC Therapeutics (PTCT) Jumps: Stock Rises 12.9%
finance.yahoo.com - January 9 at 10:15 AM
PTC Therapeutics Provides Corporate Update and Outlines 2018 Strategic PrioritiesPTC Therapeutics Provides Corporate Update and Outlines 2018 Strategic Priorities
finance.yahoo.com - January 8 at 10:32 AM
PTC Therapeutics (PTCT) Upgraded by Zacks Investment Research to BuyPTC Therapeutics (PTCT) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - January 7 at 11:12 PM
PTC Therapeutics, Inc. (PTCT) Given Average Recommendation of "Hold" by BrokeragesPTC Therapeutics, Inc. (PTCT) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 5 at 7:26 PM
PTC Therapeutics, Inc. (PTCT) Expected to Announce Quarterly Sales of $66.14 MillionPTC Therapeutics, Inc. (PTCT) Expected to Announce Quarterly Sales of $66.14 Million
www.americanbankingnews.com - January 4 at 2:58 AM
Contrasting PTC Therapeutics (PTCT) & Its RivalsContrasting PTC Therapeutics (PTCT) & Its Rivals
www.americanbankingnews.com - December 30 at 5:20 AM
PTC Therapeutics (PTCT) Downgraded to "Strong Sell" at ValuEnginePTC Therapeutics (PTCT) Downgraded to "Strong Sell" at ValuEngine
www.americanbankingnews.com - December 29 at 5:04 PM
How Does PTC Therapeutics Inc’s (NASDAQ:PTCT) Earnings Growth Stack Up Against Industry Performance?How Does PTC Therapeutics Inc’s (NASDAQ:PTCT) Earnings Growth Stack Up Against Industry Performance?
finance.yahoo.com - December 29 at 10:33 AM
Contrasting PTC Therapeutics (PTCT) and Its PeersContrasting PTC Therapeutics (PTCT) and Its Peers
www.americanbankingnews.com - December 28 at 9:06 PM
Reviewing PTC Therapeutics (PTCT) and Its PeersReviewing PTC Therapeutics (PTCT) and Its Peers
www.americanbankingnews.com - December 26 at 9:21 PM
PTC Therapeutics Clears Key Benchmark, Hitting 80-Plus RS RatingPTC Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating
finance.yahoo.com - December 26 at 3:41 PM
PTC Therapeutics, Inc. – Value Analysis (NASDAQ:PTCT) : December 26, 2017PTC Therapeutics, Inc. – Value Analysis (NASDAQ:PTCT) : December 26, 2017
finance.yahoo.com - December 26 at 3:41 PM
PTC Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : PTCT-US : December 25, 2017PTC Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : PTCT-US : December 25, 2017
finance.yahoo.com - December 25 at 6:05 PM
$66.14 Million in Sales Expected for PTC Therapeutics, Inc. (PTCT) This Quarter$66.14 Million in Sales Expected for PTC Therapeutics, Inc. (PTCT) This Quarter
www.americanbankingnews.com - December 19 at 2:26 PM
Head-To-Head Review: PTC Therapeutics (PTCT) versus Its CompetitorsHead-To-Head Review: PTC Therapeutics (PTCT) versus Its Competitors
www.americanbankingnews.com - December 19 at 11:24 AM
PTC Therapeutics, Inc. (PTCT) Expected to Post Earnings of -$0.23 Per SharePTC Therapeutics, Inc. (PTCT) Expected to Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - December 17 at 5:30 AM
Stocks With Rising Relative Strength: PTC TherapeuticsStocks With Rising Relative Strength: PTC Therapeutics
finance.yahoo.com - December 15 at 10:50 AM
Head-To-Head Comparison: PTC Therapeutics (PTCT) & Its RivalsHead-To-Head Comparison: PTC Therapeutics (PTCT) & Its Rivals
www.americanbankingnews.com - December 13 at 9:26 AM
Update in Lawsuit for Investors in NASDAQ:PTCT shares against PTC Therapeutics, Inc. announced by Shareholders FoundationUpdate in Lawsuit for Investors in NASDAQ:PTCT shares against PTC Therapeutics, Inc. announced by Shareholders Foundation
feeds.benzinga.com - December 12 at 10:28 AM
PTC Therapeutics, Inc. (PTCT) Given Average Recommendation of "Hold" by AnalystsPTC Therapeutics, Inc. (PTCT) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - December 11 at 10:22 PM
Head-To-Head Review: PTC Therapeutics (PTCT) & Its PeersHead-To-Head Review: PTC Therapeutics (PTCT) & Its Peers
www.americanbankingnews.com - December 7 at 3:32 AM
PTC Therapeutics (PTCT) and The Competition Critical ContrastPTC Therapeutics (PTCT) and The Competition Critical Contrast
www.americanbankingnews.com - December 5 at 7:48 AM
ETFs with exposure to PTC Therapeutics, Inc. : November 29, 2017ETFs with exposure to PTC Therapeutics, Inc. : November 29, 2017
finance.yahoo.com - November 29 at 4:48 PM
 Analysts Expect PTC Therapeutics, Inc. (PTCT) Will Announce Earnings of -$0.23 Per Share Analysts Expect PTC Therapeutics, Inc. (PTCT) Will Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - November 29 at 1:14 AM
PTC Therapeutics, Inc. (PTCT) Price Target Increased to $15.00 by Analysts at J P Morgan Chase & CoPTC Therapeutics, Inc. (PTCT) Price Target Increased to $15.00 by Analysts at J P Morgan Chase & Co
www.americanbankingnews.com - November 24 at 2:02 PM
Traders Purchase High Volume of PTC Therapeutics Put Options (PTCT)Traders Purchase High Volume of PTC Therapeutics Put Options (PTCT)
www.americanbankingnews.com - November 17 at 2:54 AM
Comparing PTC Therapeutics (PTCT) & Vital Therapies (VTL)Comparing PTC Therapeutics (PTCT) & Vital Therapies (VTL)
www.americanbankingnews.com - November 16 at 1:08 PM
PTC Therapeutics, Inc. (PTCT) Upgraded to Neutral at J P Morgan Chase & CoPTC Therapeutics, Inc. (PTCT) Upgraded to Neutral at J P Morgan Chase & Co
www.americanbankingnews.com - November 16 at 9:20 AM
Daily Technical Summary Reports on Biotech Stocks -- Ophthotech, PTC ...Daily Technical Summary Reports on Biotech Stocks -- Ophthotech, PTC ...
www.prnewswire.com - November 14 at 7:00 AM
PTC Therapeutics, Inc. (PTCT) Expected to Announce Quarterly Sales of $55.33 MillionPTC Therapeutics, Inc. (PTCT) Expected to Announce Quarterly Sales of $55.33 Million
www.americanbankingnews.com - November 12 at 12:00 PM
PTC Therapeutics, Inc. (PTCT) Expected to Announce Earnings of -$0.45 Per SharePTC Therapeutics, Inc. (PTCT) Expected to Announce Earnings of -$0.45 Per Share
www.americanbankingnews.com - November 10 at 9:20 AM
PTC Therapeutics, Inc. :PTCT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017PTC Therapeutics, Inc. :PTCT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017
finance.yahoo.com - November 7 at 9:05 AM
Edited Transcript of PTCT earnings conference call or presentation 2-Nov-17 8:30pm GMTEdited Transcript of PTCT earnings conference call or presentation 2-Nov-17 8:30pm GMT
finance.yahoo.com - November 4 at 9:23 AM
PTC Therapeutics (PTCT) Receives CRL for Atalurens NDA - StreetInsider.comPTC Therapeutics (PTCT) Receives CRL for Ataluren's NDA - StreetInsider.com
www.streetinsider.com - October 27 at 11:51 AM
PTC Therapeutics Receives Complete Response Letter for Atalurens NDAPTC Therapeutics Receives Complete Response Letter for Ataluren's NDA
finance.yahoo.com - October 27 at 11:51 AM
FDA declines to approve PTCs Duchenne drugFDA declines to approve PTC's Duchenne drug
finance.yahoo.com - October 27 at 11:51 AM
ETFs with exposure to PTC Therapeutics, Inc. : October 26, 2017ETFs with exposure to PTC Therapeutics, Inc. : October 26, 2017
finance.yahoo.com - October 27 at 11:51 AM
Todays Research Reports on Trending Tickers: Keryx Biopharmaceuticals and PTC TherapeuticsToday's Research Reports on Trending Tickers: Keryx Biopharmaceuticals and PTC Therapeutics
finance.yahoo.com - October 27 at 11:51 AM
Royal Bank Of Canada Reaffirms Hold Rating for PTC Therapeutics, Inc. (PTCT)Royal Bank Of Canada Reaffirms Hold Rating for PTC Therapeutics, Inc. (PTCT)
www.americanbankingnews.com - October 25 at 11:08 PM
Cowen and Company Reaffirms Hold Rating for PTC Therapeutics, Inc. (PTCT)Cowen and Company Reaffirms Hold Rating for PTC Therapeutics, Inc. (PTCT)
www.americanbankingnews.com - October 25 at 10:28 PM
PTC Therapeutics, Inc. (PTCT) to Release Earnings on TuesdayPTC Therapeutics, Inc. (PTCT) to Release Earnings on Tuesday
www.americanbankingnews.com - October 24 at 10:38 AM
PTC Therapeutics to Present at the Credit Suisse 26th Annual Healthcare ConferencePTC Therapeutics to Present at the Credit Suisse 26th Annual Healthcare Conference
finance.yahoo.com - October 24 at 8:51 AM
PTC Therapeutics, Inc. (PTCT) Receives Consensus Recommendation of "Hold" from AnalystsPTC Therapeutics, Inc. (PTCT) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 22 at 8:38 PM

SEC Filings

PTC Therapeutics (NASDAQ:PTCT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

PTC Therapeutics (NASDAQ:PTCT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

PTC Therapeutics (NASDAQ PTCT) Stock Chart for Saturday, January, 20, 2018

Loading chart…

This page was last updated on 1/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.